- Biogen (NASDAQ:BIIB) Q1 results: Revenues: $2,810.7M (+3.1%); Product Sales: $2,380.1M (+3.1%).
- Operating Income: $1,024.3M (-25.7%); Net Income: $747.6M (-23.0%); EPS: $3.46 (-21.9%); Non-GAAP EPS: $5.20 (+8.6%); Quick Assets: $2,880.2M (-41.2%).
- Key Product Sales: Tecfidera: $958M (+1.3%); Total Interferon: $648M (-3.3%); Avonex: $537M (-4.8%); Plegridy: $112M (+5.7%); Tysabri: $545M (+14.3%); Eloctate: $48M (-55.6%); Alprolix: $26M (-65.3%); Spinraza: $47M; Anti-CD20 Revenues: $341M (+3.6%).
- Shares are up 4% premarket on average volume.